Annual Report 2016 of Square Pharmaceuticals Limited

It is a broadly described annual report of Square Pharmaceuticals Limited in the year of 2015-2016. The company contributed an amount of Taka. 9,084,720,519 (including Tk. 66,455,598 as contribution as duty/taxes towards machinery & spare parts imports) to National Exchequer as against Taka. 6,314,740,042 in the previous year. During the financial year, The Company’s Gross Revenue Tk. 41,678,779,532. Cost of Goods Sold Tk. 18,625,695,479. Gross Profit Tk. 17,407,356,173. Profit before tax Tk. 12,213,964,722 Net Profit after Tax for the year ended (15 Months Period) Tk. 9,226,614,674. The Earning per Share of Tk. 14.80 is based on increased outstanding 623,586,546 shares of Tk. 10 each. However, if the original issued capital at the time of IPO is considered, the EPS would stand at Tk. 922.66 in 2015-2016 as against Tk. 652.39 in 2014-2015.

The Board of Directors proposed and recommended for the declaration of Cash Dividend @40% for the year 2015-2016. The Board also recommended for the declaration of Stock Dividend (Bonus Shares) @10%. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.

More Annual Report of Square Pharmaceuticals Limited: